[시장보고서]바이오의약품 시장 규모, 점유율, 동향 분석 보고서 : 분자별, 질환별, 약물 유형별, 개발 단계 유형별, 투여 경로별, 처방 유형별, 판매 채널별, 지역별, 부문별 예측(2026-2033년)

바이오의약품 시장 규모, 점유율, 동향 분석 보고서 : 분자별, 질환별, 약물 유형별, 개발 단계 유형별, 투여 경로별, 처방 유형별, 판매 채널별, 지역별, 부문별 예측(2026-2033년)

Biopharmaceutical Market Size, Share & Trends Analysis Report By Molecule, By Disease, By Drug Type, By Drug Development Type, By Route Of Administration, By Prescription Type, By Sales Channel, By Region, And Segment Forecasts, 2026 - 2033

상품코드 : 1908571

리서치사 : Grand View Research

발행일 : 2025년 12월

페이지 정보 : 영문 255 Pages

라이선스 & 가격 (부가세 별도)

US $ 5,950

￦ 8,698,000

Unprintable PDF & Excel (Single User License)

보고서 PDF 및 엑셀을 1인만 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 불가능합니다.

US $ 6,950

￦ 10,160,000

Printable PDF & Excel (5-User License)

보고서 PDF 및 엑셀을 동일 기업 내 동일 부서에서 최대 5명까지 사용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다.

US $ 8,950

￦ 13,084,000

Printable PDF & Excel (Enterprise License)

PDF & Excel 보고서를 동일 기업(자회사 포함)의 모든 분이 이용할 수 있는 라이선스입니다. 텍스트 등의 복사 및 붙여넣기, 인쇄는 가능합니다. 인쇄물의 이용 범위는 파일의 이용 범위와 동일합니다.

ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.

한글목차

샘플 요청 목록에 추가

바이오의약품 시장 개요

세계의 바이오의약품 시장 규모는 2025년에 4억 8,438만 달러로 추정되며, 2033년에 8억 1,630만 달러에 달할 것으로 예측됩니다.

2026-2033년 사이에는 CAGR 6.55%로 성장할 것으로 예상됩니다. 바이오의약품 산업의 성장은 표적 치료제에 대한 수요 증가, 생명공학 기술의 발전, 만성질환의 유병률 증가, 인구 고령화 등의 요인에 의해 주도되고 있습니다.

바이오제약 산업은 생명공학 및 의약품 개발의 눈부신 발전에 힘입어 급속한 성장세를 보이고 있습니다. 백신 기술, 단클론항체, 유전자 치료, 차세대 바이오의약품의 혁신은 여러 치료 영역에서 치료 패러다임을 바꾸고 있습니다. 이러한 획기적인 발전은 치료 효과를 높이고, 환자 예후를 개선하며, 미충족 수요를 충족시키는 데 기여하고 있습니다. 최근 동향은 이러한 발전이 세계 헬스케어 환경에 미치는 영향을 강조하고, 질병 퇴치에 있어 바이오의약품의 매우 중요한 역할을 강조하고 있습니다.

2025년 2월, 자이더스 라이프사이언스는 인도 최초의 4가 독감 백신 'VaxiFlu-4'를 발표하며 백신 기술에서 큰 도약을 이루었습니다. 아메다바드에 위치한 백신 기술 센터에서 개발된 이 신종 인플루엔자 예방 백신은 신종 인플루엔자 바이러스 변종에 대응하기 위해 WHO가 권장하는 구성에 따라 제조되었습니다. 중앙 의약품 연구소의 승인을 받은 VaxiFlu-4는 독감 유행 예방과 공중보건 문제 해결에 중요한 역할을 할 것으로 기대됩니다. 이 혁신은 백신 개발의 진전이 질병 예방 전략을 강화하고 바이오 제약 산업의 성장에 기여하는 실례를 보여주고 있습니다.

지역별 시장 점유율 분석, 2025년과 2033년
지역별 시장 대시보드
시장 규모와 예측, 동향 분석(2021-2033년)
북미
- 미국
- 캐나다
- 멕시코
유럽
- 영국
- 독일
- 프랑스
- 이탈리아
- 스페인
- 덴마크
- 스웨덴
- 노르웨이
아시아태평양
- 일본
- 중국
- 인도
- 호주
- 한국
- 태국
라틴아메리카
- 브라질
- 아르헨티나
중동 및 아프리카
- 남아프리카공화국
- 사우디아라비아
- 아랍에미리트
- 쿠웨이트

제13장 경쟁 구도

참여 기업 개요
기업 시장 상황 분석
기업 분류
전략 매핑
기업 개요/리스트
- F. Hoffmann-La Roche Ltd
- Novartis AG
- AbbVie Inc.
- Johnson & Johnson Services, Inc.
- Merck & Co., Inc.
- Pfizer Inc.
- Bristol-Myers Squibb Company
- Sanofi
- GSK plc.
- AstraZeneca
- Takeda Pharmaceutical Company Limited
- Biogen
- Eli Lilly and Company
- Novo Nordisk A/S
- Amgen Inc.

KSM

영문 목차

영문목차

Biopharmaceutical Market Summary

The global biopharmaceutical market size was estimated at USD 484.38 million in 2025 and is projected to reach USD 816.30 million by 2033, growing at a CAGR of 6.55% from 2026 to 2033. The biopharmaceutical industry's growth is driven by increasing demand for targeted therapies, advancements in biotechnology, the rising prevalence of chronic diseases, and an aging population.

The biopharmaceutical industry is witnessing rapid growth, driven by significant advancements in biotechnology and drug development. Innovations in vaccine technology, monoclonal antibodies, gene therapies, and next-generation biologics are transforming treatment paradigms across multiple therapeutic areas. These breakthroughs enhance treatment efficacy, improve patient outcomes, and address unmet medical needs. Recent developments highlight the impact of these advancements on the global healthcare landscape, underscoring the pivotal role of biopharmaceuticals in combating diseases.

In February 2025, Zydus Lifesciences introduced VaxiFlu-4, India's first quadrivalent influenza vaccine, marking a significant leap in vaccine technology. This novel flu protection vaccine, developed at Zydus's Vaccine Technology Centre in Ahmedabad, has been formulated according to the WHO recommended composition to combat emerging strains of the influenza virus. With clearance from the Central Drug Laboratory, VaxiFlu-4 is expected to play a crucial role in preventing flu outbreaks and addressing public health challenges. This innovation exemplifies how advancements in vaccine development are bolstering disease prevention strategies and contributing to the growth of the biopharmaceutical industry.

Global Biopharmaceutical Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biopharmaceutical market report based on molecule type, disease, drug type, drug development type, formulation, route of administration, prescription type, sales channel, and region:

Molecule Type Outlook (Revenue, USD Million, 2021 - 2033)
Monoclonal Antibody
Interferon
Insulin
Growth and Coagulation Factor
Erythropoietin
Vaccine
Hormone
Others
Disease Outlook (Revenue, USD Million, 2021 - 2033)
Oncology
Blood Disorder
Metabolic Disease
Infectious Disease
Cardiovascular Disease
Neurological Disease
Immunology
Other Applications
Drug Type Outlook (Revenue, USD Million, 2021 - 2033)
Proprietary (Branded)
Biosimilars
Drug Development Type Outlook (Revenue, USD Million, 2021 - 2033)
Outsource
In-house
Formulation Outlook (Revenue, USD Million, 2021 - 2033)
Injectables (IV, IM, SC)
Inhalation/Nasal Sprays
Other Formulations
Route of Administration Outlook (Revenue, USD Million, 2021 - 2033)
Parenteral (IV, IM, SC)
Inhalation/Nasal
Other Routes
Prescription Type Outlook (Revenue, USD Million, 2021 - 2033)
Prescription Medicines
Over-the-counter (OTC) Medicines
Sales Channel Outlook (Revenue, USD Million, 2021 - 2033)
Retail Pharmacies
Non-retail
Regional Outlook (Revenue, USD Million, 2021 - 2033)
North America
- U.S.
- Canada
- Mexico
Europe
- UK
- Germany
- France
- Italy
- Spain
- Denmark
- Sweden
- Norway
Asia Pacific
- Japan
- China
- India
- Australia
- South Korea
- Thailand
Latin America
- Brazil
- Argentina
Middle East & Africa
- South Africa
- Saudi Arabia
- UAE
- Kuwait

Chapter 1. Methodology and Scope

1.1. Market Segmentation & Scope
1.2. Segment Definitions
- 1.2.1. Molecule Type
- 1.2.2. Disease
- 1.2.3. Drug Type
- 1.2.4. Drug Development Type
- 1.2.5. Formulation
- 1.2.6. Route of Administration
- 1.2.7. Prescription Type
- 1.2.8. Sales Channel
1.3. Estimates and Forecast Timeline
1.4. Research Methodology
1.5. Information Procurement
- 1.5.1. Purchased Database
- 1.5.2. GVR's Internal Database
- 1.5.3. Secondary Sources
- 1.5.4. Primary Research
1.6. Information Analysis
- 1.6.1. Data Analysis Models
1.7. Market Formulation & Data Visualization
1.8. Model Details
- 1.8.1. Commodity Flow Analysis
1.9. List of Secondary Sources
1.10. Objectives

Chapter 2. Executive Summary

2.1. Market Snapshot
2.2. Segment Snapshot
2.3. Competitive Landscape Snapshot

Chapter 3. Biopharmaceutical Market Variables, Trends, & Scope

3.1. Market Lineage Outlook
3.2. Market Dynamics
- 3.2.1. Market Driver Analysis
- 3.2.2. Market Restraint Analysis
3.3. Business Environment Analysis
- 3.3.1. Industry Analysis - Porter's Five Forces Analysis
  - 3.3.1.1. Supplier Power
  - 3.3.1.2. Buyer Power
  - 3.3.1.3. Substitution Threat
  - 3.3.1.4. Threat of New Entrants
  - 3.3.1.5. Competitive Rivalry
- 3.3.2. PESTLE Analysis
- 3.3.3. Pipeline Analysis
- 3.3.4. Pricing Analysis

Chapter 4. Biopharmaceutical Market: Molecule Type Business Analysis

4.1. Molecule Type Market Share, 2025 & 2033
4.2. Molecule Type Segment Dashboard
4.3. Market Size & Forecasts and Trend Analysis, by Molecule Type, 2021 to 2033 (USD Million)
4.4. Monoclonal Antibody
- 4.4.1. Monoclonal Antibody Market, 2021 - 2033 (USD Million)
4.5. Interferon
- 4.5.1. Interferon Market, 2021 - 2033 (USD Million)
4.6. Insulin
- 4.6.1. Insulin Market, 2021 - 2033 (USD Million)
4.7. Growth and Coagulation Factor
- 4.7.1. Growth and Coagulation Factor Market, 2021 - 2033 (USD Million)
4.8. Erythropoietin
- 4.8.1. Erythropoietin Market, 2021 - 2033 (USD Million)
4.9. Vaccine
- 4.9.1. Vaccine Market, 2021 - 2033 (USD Million)
4.10. Hormone
- 4.10.1. Hormone Market, 2021 - 2033 (USD Million)
4.11. Others
- 4.11.1. Other Type Market, 2021 - 2033 (USD Million)

Chapter 5. Biopharmaceutical Market: Disease Business Analysis

5.1. Disease Market Share, 2025 & 2033
5.2. Disease Segment Dashboard
5.3. Market Size & Forecasts and Trend Analysis, by Disease, 2021 to 2033 (USD Million)
5.4. Oncology
- 5.4.1. Oncology Market, 2021 - 2033 (USD Million)
5.5. Blood Disorder
- 5.5.1. Blood Disorder Market, 2021 - 2033 (USD Million)
5.6. Metabolic Disease
- 5.6.1. Metabolic Disease Market, 2021 - 2033 (USD Million)
5.7. Infectious Disease
- 5.7.1. Infectious Disease Market, 2021 - 2033 (USD Million)
5.8. Cardiovascular Disease
- 5.8.1. Cardiovascular Disease Market, 2021 - 2033 (USD Million)
5.9. Neurological Disease
- 5.9.1. Neurological Disease Market, 2021 - 2033 (USD Million)
5.10. Immunology
- 5.10.1. Immunology Market, 2021 - 2033 (USD Million)
5.11. Others
- 5.11.1. Other Type Market, 2021 - 2033 (USD Million)

Chapter 6. Biopharmaceutical Market: Drug Type Business Analysis

6.1. Drug Type Market Share, 2025 & 2033
6.2. Drug Type Segment Dashboard
6.3. Market Size & Forecasts and Trend Analysis, by Drug Type, 2021 to 2033 (USD Million)
6.4. Proprietary (Branded)
- 6.4.1. Proprietary (Branded) Market, 2021 - 2033 (USD Million)
- 6.4.2. Biosimilars
  - 6.4.2.1. Biosimilars Market, 2021 - 2033 (USD Million)

Chapter 7. Biopharmaceutical Market: Drug Development Type Business Analysis

7.1. Drug Development Type Market Share, 2025 & 2033
7.2. Drug Development Type Segment Dashboard
7.3. Market Size & Forecasts and Trend Analysis, by Drug Development Type, 2021 to 2033 (USD Million)
7.4. Outsource
- 7.4.1. Outsource Market, 2021 - 2033 (USD Million)
7.5. In-house
- 7.5.1. In-house Market, 2021 - 2033 (USD Million)

Chapter 8. Biopharmaceutical Market: Formulation Business Analysis

8.1. Formulation Market Share, 2025 & 2033
8.2. Formulation Segment Dashboard
8.3. Market Size & Forecasts and Trend Analysis, by Formulation, 2021 to 2033 (USD Million)
8.4. Injectables (IV, IM, SC)
- 8.4.1. Injectables (IV, IM, SC) Market, 2021 - 2033 (USD Million)
8.5. Inhalation/Nasal Sprays
- 8.5.1. Inhalation/Nasal Sprays Market, 2021 - 2033 (USD Million)
8.6. Other Formulations
- 8.6.1. Other Formulations Market, 2021 - 2033 (USD Million)

Chapter 9. Biopharmaceutical Market: Route of Administration Business Analysis

9.1. Route of Administration Market Share, 2025 & 2033
9.2. Route of Administration Segment Dashboard
9.3. Market Size & Forecasts and Trend Analysis, by Route of Administration, 2021 to 2033 (USD Million)
9.4. Parenteral (IV, IM, SC)
- 9.4.1. Parenteral (IV, IM, SC) Market, 2021 - 2033 (USD Million)
9.5. Inhalation/Nasal
- 9.5.1. Inhalation/Nasal Market, 2021 - 2033 (USD Million)
9.6. Other Routes
- 9.6.1. Other Routes Market, 2021 - 2033 (USD Million)

Chapter 10. Biopharmaceutical Market: Prescription Type Business Analysis

10.1. Prescription Type Market Share, 2025 & 2033
10.2. Prescription Type Segment Dashboard
10.3. Market Size & Forecasts and Trend Analysis, by Prescription Type, 2021 to 2033 (USD Million)
10.4. Prescription Medicines
- 10.4.1. Prescription Medicines Market, 2021 - 2033 (USD Million)
10.5. Over-the-counter (OTC) Medicines
- 10.5.1. Over-the-counter (OTC) Medicines Market, 2021 - 2033 (USD Million)

Chapter 11. Biopharmaceutical Market: Sales Channel Business Analysis

11.1. Sales Channel Market Share, 2025 & 2033
11.2. Sales Channel Segment Dashboard
11.3. Market Size & Forecasts and Trend Analysis, by Sales Channel, 2021 to 2033 (USD Million)
11.4. Retail Pharmacies
- 11.4.1. Retail Pharmacies Market, 2021 - 2033 (USD Million)
11.5. Non-retail
- 11.5.1. Non-retail Market, 2021 - 2033 (USD Million)

Chapter 12. Biopharmaceutical Market: Regional Estimates & Trend Analysis

12.1. Regional Market Share Analysis, 2025 & 2033
12.2. Regional Market Dashboard
12.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
12.4. North America
- 12.4.1. North America Biopharmaceutical Market Estimates And Forecasts, By Country, 2021 - 2033 (USD Million)
- 12.4.2. U.S.
  - 12.4.2.1. Key Country Dynamics
  - 12.4.2.2. Target Disease Prevalence
  - 12.4.2.3. Regulatory Framework
  - 12.4.2.4. Reimbursement Framework
  - 12.4.2.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.4.3. Canada
  - 12.4.3.1. Key Country Dynamics
  - 12.4.3.2. Target Disease Prevalence
  - 12.4.3.3. Regulatory Framework
  - 12.4.3.4. Reimbursement Framework
  - 12.4.3.5. U.S. Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.4.4. Mexico
  - 12.4.4.1. Key Country Dynamics
  - 12.4.4.2. Target Disease Prevalence
  - 12.4.4.3. Regulatory Framework
  - 12.4.4.4. Reimbursement Framework
  - 12.4.4.5. Mexico Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.5. Europe
- 12.5.1. Europe Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.5.2. UK
  - 12.5.2.1. Key Country Dynamics
  - 12.5.2.2. Target Disease Prevalence
  - 12.5.2.3. Regulatory Framework
  - 12.5.2.4. Reimbursement Framework
  - 12.5.2.5. Uk Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.5.3. Germany
  - 12.5.3.1. Key Country Dynamics
  - 12.5.3.2. Target Disease Prevalence
  - 12.5.3.3. Regulatory Framework
  - 12.5.3.4. Reimbursement Framework
  - 12.5.3.5. Germany Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.5.4. France
  - 12.5.4.1. Key Country Dynamics
  - 12.5.4.2. Target Disease Prevalence
  - 12.5.4.3. Regulatory Framework
  - 12.5.4.4. Reimbursement Framework
  - 12.5.4.5. France Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.5.5. Italy
  - 12.5.5.1. Key Country Dynamics
  - 12.5.5.2. Target Disease Prevalence
  - 12.5.5.3. Regulatory Framework
  - 12.5.5.4. Reimbursement Framework
  - 12.5.5.5. Italy Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.5.6. Spain
  - 12.5.6.1. Key Country Dynamics
  - 12.5.6.2. Target Disease Prevalence
  - 12.5.6.3. Regulatory Framework
  - 12.5.6.4. Reimbursement Framework
  - 12.5.6.5. Spain Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.5.7. Denmark
  - 12.5.7.1. Key Country Dynamics
  - 12.5.7.2. Target Disease Prevalence
  - 12.5.7.3. Regulatory Framework
  - 12.5.7.4. Reimbursement Framework
  - 12.5.7.5. Denmark Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.5.8. Sweden
  - 12.5.8.1. Key Country Dynamics
  - 12.5.8.2. Target Disease Prevalence
  - 12.5.8.3. Regulatory Framework
  - 12.5.8.4. Reimbursement Framework
  - 12.5.8.5. Sweden Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.5.9. Norway
  - 12.5.9.1. Key Country Dynamics
  - 12.5.9.2. Target Disease Prevalence
  - 12.5.9.3. Regulatory Framework
  - 12.5.9.4. Reimbursement Framework
  - 12.5.9.5. Norway Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.6. Asia Pacific
- 12.6.1. Asia Pacific Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.6.2. Japan
  - 12.6.2.1. Key Country Dynamics
  - 12.6.2.2. Target Disease Prevalence
  - 12.6.2.3. Regulatory Framework
  - 12.6.2.4. Reimbursement Framework
  - 12.6.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.6.3. China
  - 12.6.3.1. Key Country Dynamics
  - 12.6.3.2. Target Disease Prevalence
  - 12.6.3.3. Regulatory Framework
  - 12.6.3.4. Reimbursement Framework
  - 12.6.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.6.4. India
  - 12.6.4.1. Key Country Dynamics
  - 12.6.4.2. Target Disease Prevalence
  - 12.6.4.3. Regulatory Framework
  - 12.6.4.4. Reimbursement Framework
  - 12.6.4.5. India Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.6.5. Australia
  - 12.6.5.1. Key Country Dynamics
  - 12.6.5.2. Target Disease Prevalence
  - 12.6.5.3. Regulatory Framework
  - 12.6.5.4. Reimbursement Framework
  - 12.6.5.5. Australia Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.6.6. South Korea
  - 12.6.6.1. Key Country Dynamics
  - 12.6.6.2. Target Disease Prevalence
  - 12.6.6.3. Regulatory Framework
  - 12.6.6.4. Reimbursement Framework
  - 12.6.6.5. South Korea Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.6.7. Thailand
  - 12.6.7.1. Key Country Dynamics
  - 12.6.7.2. Target Disease Prevalence
  - 12.6.7.3. Regulatory Framework
  - 12.6.7.4. Reimbursement Framework
  - 12.6.7.5. Thailand Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.7. Latin America
- 12.7.1. Latin America Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.7.2. Brazil
  - 12.7.2.1. Key Country Dynamics
  - 12.7.2.2. Target Disease Prevalence
  - 12.7.2.3. Regulatory Framework
  - 12.7.2.4. Reimbursement Framework
  - 12.7.2.5. Japan Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.7.3. Argentina
  - 12.7.3.1. Key Country Dynamics
  - 12.7.3.2. Target Disease Prevalence
  - 12.7.3.3. Regulatory Framework
  - 12.7.3.4. Reimbursement Framework
  - 12.7.3.5. China Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
12.8. Middle East and Africa
- 12.8.1. Middle East and Africa Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.8.2. South Africa
  - 12.8.2.1. Key Country Dynamics
  - 12.8.2.2. Target Disease Prevalence
  - 12.8.2.3. Regulatory Framework
  - 12.8.2.4. Reimbursement Framework
  - 12.8.2.5. South Africa Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.8.3. Saudi Arabia
  - 12.8.3.1. Key Country Dynamics
  - 12.8.3.2. Target Disease Prevalence
  - 12.8.3.3. Regulatory Framework
  - 12.8.3.4. Reimbursement Framework
  - 12.8.3.5. Saudi Arabia Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.8.4. UAE
  - 12.8.4.1. Key Country Dynamics
  - 12.8.4.2. Target Disease Prevalence
  - 12.8.4.3. Regulatory Framework
  - 12.8.4.4. Reimbursement Framework
  - 12.8.4.5. UAE Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)
- 12.8.5. Kuwait
  - 12.8.5.1. Key Country Dynamics
  - 12.8.5.2. Target Disease Prevalence
  - 12.8.5.3. Regulatory Framework
  - 12.8.5.4. Reimbursement Framework
  - 12.8.5.5. Kuwait Biopharmaceutical Market Estimates and Forecasts, 2021 - 2033 (USD Million)

Chapter 13. Competitive Landscape

13.1. Participant Overview
13.2. Company Market Position Analysis
13.3. Company Categorization
13.4. Strategy Mapping
13.5. Company Profiles/Listing
- 13.5.1. F. Hoffmann-La Roche Ltd
  - 13.5.1.1. Overview
  - 13.5.1.2. Financial Performance
  - 13.5.1.3. Product Benchmarking
  - 13.5.1.4. Strategic Initiatives
- 13.5.2. Novartis AG
  - 13.5.2.1. Overview
  - 13.5.2.2. Financial Performance
  - 13.5.2.3. Product Benchmarking
  - 13.5.2.4. Strategic Initiatives
- 13.5.3. AbbVie Inc.
  - 13.5.3.1. Overview
  - 13.5.3.2. Financial Performance
  - 13.5.3.3. Product Benchmarking
  - 13.5.3.4. Strategic Initiatives
- 13.5.4. Johnson & Johnson Services, Inc.
  - 13.5.4.1. Overview
  - 13.5.4.2. Financial Performance
  - 13.5.4.3. Product Benchmarking
  - 13.5.4.4. Strategic Initiatives
- 13.5.5. Merck & Co., Inc.
  - 13.5.5.1. Overview
  - 13.5.5.2. Financial Performance
  - 13.5.5.3. Product Benchmarking
  - 13.5.5.4. Strategic Initiatives
- 13.5.6. Pfizer Inc.
  - 13.5.6.1. Overview
  - 13.5.6.2. Financial Performance
  - 13.5.6.3. Product Benchmarking
  - 13.5.6.4. Strategic Initiatives
- 13.5.7. Bristol-Myers Squibb Company
  - 13.5.7.1. Overview
  - 13.5.7.2. Financial Performance
  - 13.5.7.3. Product Benchmarking
  - 13.5.7.4. Strategic Initiatives
- 13.5.8. Sanofi
  - 13.5.8.1. Overview
  - 13.5.8.2. Financial Performance
  - 13.5.8.3. Product Benchmarking
  - 13.5.8.4. Strategic Initiatives
- 13.5.9. GSK plc.
  - 13.5.9.1. Overview
  - 13.5.9.2. Financial Performance
  - 13.5.9.3. Product Benchmarking
  - 13.5.9.4. Strategic Initiatives
- 13.5.10. AstraZeneca
  - 13.5.10.1. Overview
  - 13.5.10.2. Financial Performance
  - 13.5.10.3. Product Benchmarking
  - 13.5.10.4. Strategic Initiatives
- 13.5.11. Takeda Pharmaceutical Company Limited
  - 13.5.11.1. Overview
  - 13.5.11.2. Financial Performance
  - 13.5.11.3. Product Benchmarking
  - 13.5.11.4. Strategic Initiatives
- 13.5.12. Biogen
  - 13.5.12.1. Overview
  - 13.5.12.2. Financial Performance
  - 13.5.12.3. Product Benchmarking
  - 13.5.12.4. Strategic Initiatives
- 13.5.13. Eli Lilly and Company
  - 13.5.13.1. Overview
  - 13.5.13.2. Financial Performance
  - 13.5.13.3. Product Benchmarking
  - 13.5.13.4. Strategic Initiatives
- 13.5.14. Novo Nordisk A/S
  - 13.5.14.1. Overview
  - 13.5.14.2. Financial Performance
  - 13.5.14.3. Product Benchmarking
  - 13.5.14.4. Strategic Initiatives
- 13.5.15. Amgen Inc.
  - 13.5.15.1. Overview
  - 13.5.15.2. Financial Performance
  - 13.5.15.3. Product Benchmarking
  - 13.5.15.4. Strategic Initiatives

한글목차

바이오의약품 시장 개요

목차

제1장 조사 방법과 범위

제2장 주요 요약

제3장 바이오의약품 시장 변수, 동향, 범위

제4장 바이오의약품 시장 : 분자별 비즈니스 분석

제5장 바이오의약품 시장 : 질환별 비즈니스 분석

제6장 바이오의약품 시장 : 약물 유형별 비즈니스 분석

제7장 바이오의약품 시장 : 개발 단계 유형별 비즈니스 분석

제8장 바이오의약품 시장 : 제제별 비즈니스 분석

제9장 바이오의약품 시장 : 투여 경로별 비즈니스 분석

제10장 바이오의약품 시장 : 처방 유형별 비즈니스 분석

제11장 바이오의약품 시장 : 판매 채널별 비즈니스 분석

제12장 바이오의약품 시장 : 지역별, 추정·동향 분석